| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $759.9M | — | +27.0% |
| Cost of Revenue | $234.1M | — | +19.8% |
| R&D Expense | $36.5M | — | +10.4% |
| SG&A Expense | $297.8M | — | +22.6% |
| Operating Income | $150.4M | — | +55.0% |
| Pre-tax Income | $157.1M | — | +51.5% |
| Income Tax | $32.8M | — | +16.2% |
| Net Income | $124.3M | — | +64.7% |
| EPS (Basic) | $0.92 | — | +67.3% |
| EPS (Diluted) | $0.90 | — | +66.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $561.0M | +6.6% | — |
| Short-term Investments | $68.9M | +121.6% | — |
| Accounts Receivable | $686.4M | +1.1% | +28.3% |
| Inventory | $772.6M | +1.8% | +16.4% |
| Current Assets | $2.20B | +3.4% | +28.5% |
| Total Assets | $5.44B | +2.6% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $202.4M | — | +14.1% |
| Capital Expenditures | $39.6M | — | +9.7% |
| Investing Cash Flow | -$182.7M | — | -239.0% |
| Financing Cash Flow | $18.2M | — | +102.9% |
| Free Cash Flow | $162.7M | — | +15.3% |
| +15.5% |
| Current Liabilities | $482.5M | -3.2% | +25.4% |
| Total Liabilities | $707.2M | -3.1% | +13.5% |
| Stockholders' Equity | $4.73B | +3.5% | +15.8% |